Heron Therapeutics, Inc. (HRTX)

Market Cap	331.06M
Revenue (ttm)	148.52M
Net Income (ttm)	-7.79M
Shares Out	152.56M
EPS (ttm)	-0.06
PE Ratio	n/a
Forward PE	246.59
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,294,106
Open	2.050
Previous Close	2.070
Day's Range	2.035 - 2.230
52-Week Range	1.040 - 3.730
Beta	1.17
Analysts	Strong Buy
Price Target	5.00 (+130.95%)
Earnings Date	Aug 5, 2025

About HRTX

Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company’s product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emeto...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Aug 26, 1987
• Employees: 122
• Stock Exchange: NASDAQ
• Ticker Symbol: HRTX
• Website: https://www.herontx.com

Financial Performance

In 2024, Heron Therapeutics's revenue was $144.29 million, an increase of 13.57% compared to the previous year's $127.04 million. Losses were -$13.58 million, -87.72% less than in 2023.

Analyst Summary

According to 2 analysts, the average rating for HRTX stock is "Strong Buy." The 12-month stock price target is $5.0, which is an increase of 130.95% from the latest price.

Price Target

$5.0

(130.95% upside)

Analyst Consensus: Strong Buy